⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
LLY News
Eli Lilly & Co.
CytoHub Co-Founder Aitor Aguirre Named to Lead Cardiac Tissue Engineering at NIH's First National Organoid Center
businesswire.com
JNJ
SNY
LLY
NVDA
Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
prnewswire.com
LLY
Lilly's Foundayo (orforglipron) 17.2 mg showed greater weight loss and A1C reduction than oral semaglutide 25 mg among adults with type 2 diabetes in a new indirect treatment comparison
prnewswire.com
LLY
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
prnewswire.com
LLY
RVMD
ONCY
AMGN
VSTM
Lilly launches the Lilly Change the Course Commitment, aiming to address treatment gaps in diabetes and obesity in LMICs
prnewswire.com
LLY
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
prnewswire.com
LLY
Breast Cancer Continues to Impact Communities; Austin Rallies Together to Take Action at Susan G. Komen® Austin MORE THAN PINK Walk
businesswire.com
DELL
BAC
NTRA
LLY
NVS
Microservices in Healthcare Market Set for Strong Growth Through 2035 as Cloud Adoption, Modular Applications and Digital Transformation Unlock New Opportunities
globenewswire.com
AMZN
MSFT
GOOGL
ORCL
IBM
LLY
PFE
Global Autoimmune Treatment Market to Reach USD 321.95 Billion by 2034, Driven by Rising Prevalence of Autoimmune Diseases, Growing Adoption of Biologics, and Advances in Precision Medicine Says Maximize Market Research
prnewswire.com
ABBV
JNJ
AMGN
BMY
PFE
NVS
SNY
LLY
AZN
UCB
BIIB
VTRS
GILD
KYMR
Inagene launches GLP-1 Insights Program combining genetic insights with registered dietitian support to help Canadians understand their genetic response to weight management and diabetes medications
globenewswire.com
NVO
LLY